TP53 and cancer: SCLC shows near-ubiquitous loss of function of the RB1 and TP53 tumor suppressor genes (George et al. 2015), but a better characterization of the genetic drivers of this cancer and the contribution of its potential cells of origin to tumor characteristics are needed for developing more effective therapies.